These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3083201)

  • 1. The aldose reductase inhibitor site.
    Kador PF; Kinoshita JH; Sharpless NE
    Metabolism; 1986 Apr; 35(4 Suppl 1):109-13. PubMed ID: 3083201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophor requirements of the aldose reductase inhibitor site.
    Kador PF; Sharpless NE
    Mol Pharmacol; 1983 Nov; 24(3):521-31. PubMed ID: 6415401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors.
    Srivastava SK; Petrash JM; Sadana IJ; Ansari NH; Partridge CA
    Curr Eye Res; 1982-1983; 2(6):407-10. PubMed ID: 6820339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the susceptibility of various aldose reductases to inhibition. II.
    Kador PF; Kinoshita JH; Tung WH; Chylack LT
    Invest Ophthalmol Vis Sci; 1980 Aug; 19(8):980-2. PubMed ID: 6773903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an aldose reductase inhibitor site by affinity labeling.
    Kador PF; Lee YS; Rodriguez L; Sato S; Bartoszko-Malik A; Abdel-Ghany YS; Miller DD
    Bioorg Med Chem; 1995 Oct; 3(10):1313-24. PubMed ID: 8564397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of aldose reductase and its inhibition on sugar cataract formation.
    Kador PF; Akagi Y; Kinoshita JH
    Metabolism; 1986 Apr; 35(4 Suppl 1):15-9. PubMed ID: 3083204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of irreversible inhibitors of aldose reductase.
    Ares JJ; Kador PF; Miller DD
    J Med Chem; 1986 Nov; 29(11):2384-9. PubMed ID: 3097318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
    Williams WF; Odom JD
    Science; 1986 Jul; 233(4760):223-5. PubMed ID: 3088727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIH conference. Aldose reductase and complications of diabetes.
    Cogan DG; Kinoshita JH; Kador PF; Robison G; Datilis MB; Cobo LM; Kupfer C
    Ann Intern Med; 1984 Jul; 101(1):82-91. PubMed ID: 6203454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of aldehyde reductase by aldose reductase inhibitors.
    Sato S; Kador PF
    Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type.
    Poulsom R
    Biochem Pharmacol; 1987 May; 36(10):1577-81. PubMed ID: 3109423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008].
    Tasaka H; Akagi Y; Yoshikawa T; Ikebe H; Takahashi Y; Chamoto K; Miyamoto Y; Terubayashi H
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):246-53. PubMed ID: 3111200
    [No Abstract]   [Full Text] [Related]  

  • 14. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H; Yaginuma T; Mizuno A
    Nippon Ganka Gakkai Zasshi; 1988 Jan; 92(1):194-201. PubMed ID: 3133929
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts.
    Müller P; Hockwin O; Ohrloff C
    Ophthalmic Res; 1985; 17(2):115-9. PubMed ID: 3920598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
    Unakar N; Tsui J; Johnson M
    Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro expression of rat lens aldose reductase in Escherichia coli.
    Old SE; Sato S; Kador PF; Carper DA
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):4942-5. PubMed ID: 2114645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
    Kador PF; Kinoshita JH; Sharpless NE
    J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.